DMTC

DMTC Ltd is an Australian not-for-profit company that facilitates collaborative research and development between industry, academic institutions, and government agencies. Through its Health Security Systems Australia (HSSA) division, the company leads national initiatives in medical countermeasures, including the development of vaccines, therapeutics, and diagnostic technologies to protect against chemical, biological, and radiological threats. DMTC operates as a strategic integrator and program manager rather than a traditional drug developer, focusing on enhancing sovereign industrial capability and national health security preparedness. Its portfolio includes high-priority projects such as a next-generation Q fever vaccine and advanced point-of-care diagnostic platforms for infectious diseases. By leveraging a co-investment model, DMTC accelerates the translation of research into practical solutions for the defense and public health sectors.